In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis sees no 2012 revenue slippage despite Diovan and Tekturna

This article was originally published in Scrip

Executive Summary

Novartis believes its sales this year can match those of 2011, despite the expiry of the patent on its best-selling antihypertensive drug Diovan (valsartan) and the unwelcome trial results late last year for the newer antihypertensive Tekturna/Rasilez (aliskiren), which has led to the company advising doctors to avoid using it in certain patients. The upbeat forecast came as the Swiss group reported a 4% increase in fourth-quarter sales to $14.8 billion and a 16% increase in full-year sales to $48.6 billion for 2011.

You may also be interested in...



Pfizer, Fosun Partner BioNTech On mRNA COVID-19 Vaccine

BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.

CureVac’s German Owner Rejects US Coronavirus Vaccine Grab

Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.

Buyers And Sellers: How Corporate Transactions Are Shaping Pharma

Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.

Topics

Related Companies

UsernamePublicRestriction

Register

SC016058

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel